A recent Danish study published in the BMJ (British Medical Journal) found that women taking oral contraceptives containing drospirenone, including Yasmin and Yaz, are at least at twice the risk of a venous thromboembolic event (VTE) than women taking older forms of oral contraceptives.
VTE consists of two potentially life–threatening conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot forms in the deep veins of the legs, whereas a PE is when a blood clot (often a DVT) travels from somewhere else in the body and blocks the main artery of the lungs.
The study was performed over the course of nine years, and evaluated 1.3 million women on Denmark’s National Registry on Patients. All patients reviewed were aged 15-49, non-pregnant and had no history of thrombotic disease..
BMJ published these findings yesterday, and the results have drawn special attention in light of the lawsuits involving Yaz, Yasmin and Ocella that continue to mount.
The suits are filed against Bayer Corporation, the maker of the above-mentioned birth control pills, and the cases have been consolidated into Multi-District Litigation in the Southern District of Illinois under U.S. District Court Judge David R. Herndon.
The Food and Drug Administration (FDA) is also investigating the link between drospirenone-containing birth controls and blood clots, and according the New York Times, the FDA’s preliminary findings also confirm that women taking these drugs are at least 1.5 times more likely to suffer a clot.
The FDA is set to hear from two advisory committees on the risks and benefits of the drug on December 8th of this year.
For more information on Yaz, Yasmin and Ocella birth control, blood clots and pulmonary embolisms, contact us toll-free at 888.841.9623 or via email at Anneke@ToledoLaw.com.